Cannabis research is looking up
By IHR Magazine, . Updated
EVIO Inc.,a leading North American provider of cannabis testing and scientific research for the regulated cannabis industry, has announced the launch of its EVIO Biosciences Division, which will be led by EVIO’s chief science officer, Dr. Anthony Smith. This allows EVIO to leverage its scientific and human capital expertise to focus on development of intellectual property and research. The division’s goals encompass emerging health benefits and advanced delivery modes for cannabinoids and cannabis products to the human endocannabinoid system.
“We are expanding the life sciences part of the company to focus on the need for bioscience applications in cannabis, in addition to analytical testing services. We are focusing on scientific research to support biotechnology and IP development for advanced formulation, manufacturing and delivery processes,” said Smith, who brings more than 15 years of natural product research, quality assurance, product development and more to EVIO Labs and EVIO Biosciences.
EVIO Biosciences will explore combination drug therapeutics through in vitro and clinical research. The new division reflects the growing need for education and broader dissemination of cannabis and cannabinoid biotechnology research in the scientific and medical community, particularly in the face of the widespread changes to cannabis regulation worldwide.
“One exciting project is developing cannabinoid receptor biochemistry models aimed at discovering the future of cannabis medicine. The real benefit will be leveraging our research and development, in partnership with medical and healthcare providers to bring solutions to real world health problems,” Smith concluded.
Sections: Industry News
More in Industry News
- Jungbunzlauer’s New Director Lands in the Middle of a Citric Acid Duty Fight
- NHP labelling Bulletin 13 turns two relabels into one reprint
- CHFA Launch Pad 2026 : deux finalistes québécois, et ni l’un ni l’autre n’a besoin d’une licence de Santé Canada
- CHFA Launch Pad 2026: Canada’s Innovation Pipeline Has Left the Supplement Aisle
- Retailers Want Inventory AI. Almost None Have It.
- The Ingredient Aisle Is Reorganising Around Proof — and That’s Where Niche Retailers Win